- Home
- Services
- Gallery
- Media
- Testimonials
- Review
- Blog
- Contact
- Site map
- Request a Consultation
- Search
- Glossary
Letybo received FDA approval early in 2024, becoming the sixth neuromodulator to receive such a distinction. Following in the footsteps of the Botox, Dysport, Xeomin, Jeuveau and Daxxify, Letybo enters the with a strong track-record of safety and effectiveness in the Asian, European and Australian cosmetic markets.
All the neuromodulators come from formulations of botulinum toxin A, one of seven of the serotypes present in nature, and consist of the core protein with differing accessory proteins.
| Type | Molecular Weight |
|---|---|
| Botox (onabotulinumtoxinA) | ~900 kDa |
| Dysport (abobotulinumtoxinA) | ~500 kDa |
| Xeomin (incobotulinumtoxinA) | ~150 kDa |
| Daxxify (daxbotulinumtoxinA) | ~900 kDa |
| Letybo | ~900 kDa |
The differing configuration of accessory proteins can affect the way each neuromodulator diffuses and exerts its effect on the target muscle, creating subtle differences in the time to onset, activation pattern and ultimately on the appearance of facial wrinkles.
Letybo was launched into the Korean market (as Botulax) in 2010, and grew quickly into the market leader. Since its release, Letybo has sold over 26 million vials in over 50 different countries, has been the leading neurotoxin brand in South Korea for the past seven consecutive years, and is now poised to become one of the significant players in the United States neurotoxin market.
FDA approval was supported by positive results from three phase III trials that enrolled 1,271 subjects in the U.S. and Europe. Letybo demonstrated efficacy and a convincing safety profile in the treatment of glabellar lines (the wrinkles or “11s” in between your eyebrows).
Similar to other neuromodulators like Botox and Dysport, Letybo works by injection into the muscle causing dynamic rhytids or wrinkles. Choosing an experienced aesthetic provider ensures safe and effective results as precise placement of Letybo into the target muscle will allow for the most aesthetically pleasing and natural results.
After treatment Letybo diffuses into the neuromuscular junction of the muscle, causing the muscle to relax and thereby prevent the lines and wrinkles that come from that muscle contracting.
For the frown lines, the corrugator supercilii, depressor supercilii and procerus muscles are commonly targested. For the crow’s feet, or periorbital rhytids, the orbicularis oculi is targeted, and for horizontal forehead lines the frontalis muscle is targeted.
With Letybo the effects of the treatment will start to to visible within a few days, with full effect typically in about a week. Many patients have found this time of onset to be slightly quicker than Botox. Results will last for approximately 3-4 months, which is in line with its competitors. Letybo has demonstrated an extremely safe side effect profile in the Asian and European markets, and in its three FDA clinical trials. Patients have noted that Letybo seems to diffuse smoothly and evenly, creating a natural and “softer” appearance than some of its competitors such as Botox.
Skepticism is natural, especially in a market where patient trust and outcomes are everything. That said, innovation always starts with curiosity and careful observation. The more options we have, the better we can personalize care. In some cases, Letybo may offer a better fit for a patient’s goals, and being able to offer that option is a strength, not a risk.
Dr. Yoo looks forward to taking you from pretty to prettier®.
Request Consultation
 |
Copyright © 2012-2025 Donald B. Yoo, M.D. 